WO2010017265A3 - Injectable extended release compositions containing an ion channel blocker for the treatment of arthritis - Google Patents

Injectable extended release compositions containing an ion channel blocker for the treatment of arthritis Download PDF

Info

Publication number
WO2010017265A3
WO2010017265A3 PCT/US2009/052796 US2009052796W WO2010017265A3 WO 2010017265 A3 WO2010017265 A3 WO 2010017265A3 US 2009052796 W US2009052796 W US 2009052796W WO 2010017265 A3 WO2010017265 A3 WO 2010017265A3
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
treatment
compositions containing
extended release
ion channel
Prior art date
Application number
PCT/US2009/052796
Other languages
French (fr)
Other versions
WO2010017265A2 (en
Inventor
Martin Becker
Original Assignee
Calosyn Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calosyn Pharma filed Critical Calosyn Pharma
Publication of WO2010017265A2 publication Critical patent/WO2010017265A2/en
Publication of WO2010017265A3 publication Critical patent/WO2010017265A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Abstract

Provided herein are compositions, methods, and kits that include compositions suitable for intra- articular administration to a joint of a patient suffering from osteoarthritis and that include a biocompatible matrix; and at least one ion-channel regulator.
PCT/US2009/052796 2008-08-07 2009-08-05 Injectable extended release compositions and methods of treating arthritis using same WO2010017265A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8698308P 2008-08-07 2008-08-07
US61/086,983 2008-08-07

Publications (2)

Publication Number Publication Date
WO2010017265A2 WO2010017265A2 (en) 2010-02-11
WO2010017265A3 true WO2010017265A3 (en) 2011-09-29

Family

ID=41664181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052796 WO2010017265A2 (en) 2008-08-07 2009-08-05 Injectable extended release compositions and methods of treating arthritis using same

Country Status (1)

Country Link
WO (1) WO2010017265A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP3206672B1 (en) 2015-10-27 2018-03-14 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
EP4322923A1 (en) 2021-04-16 2024-02-21 Fondazione Istituto Italiano di Tecnologia Polymeric microparticles for the local treatment of chronic inflammatory diseases
CA3228122A1 (en) * 2021-08-06 2023-02-09 Reid GRIMES Therapeutics and method for treating osteoarthritis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6221861B1 (en) * 1998-07-10 2001-04-24 The Regents Of The University Of California Reducing pyrophosphate deposition with calcium antagonists
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20060270716A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Method for treating osteoarthritis
WO2009129531A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060269579A1 (en) 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6221861B1 (en) * 1998-07-10 2001-04-24 The Regents Of The University Of California Reducing pyrophosphate deposition with calcium antagonists
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20060270716A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Method for treating osteoarthritis
WO2009129531A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier

Also Published As

Publication number Publication date
WO2010017265A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
PH12020550450A1 (en) Certain chemical entities, compositions and methods
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
WO2009076676A3 (en) Compositions and methods for producing isoprene
NZ599507A (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010025295A3 (en) Compounds that modulate intracellular calcium
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2008147797A3 (en) Ion channel modulators and methods of use
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
WO2009114601A3 (en) Preparation of lenalidomide
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2010009200A3 (en) Methods for treating oral cavity infections with chlorine dioxide
WO2009038673A3 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
WO2011034962A3 (en) Compounds that modulate intracellular calcium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09797211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09797211

Country of ref document: EP

Kind code of ref document: A2